GIPC1 and neoplasm: However, separate studies have shown convincing evidence that tumour cell expression of the transcription factor MAF strongly correlates with antimetastatic effects of Zol (28), and combined high expression levels of GIPC1 and CAPG strongly correlate with increased likelihood of developing distant recurrence in bone, with this genotype also conferring increased antitumour sensitivity to adjuvant Zol (24).